Systemic alpha-interferon in multiple sclerosis. Long-term patient follow-up.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Interferon therapy has been explored for managing MS, with varying administration routes and types.
• Long-term effects of systemic interferon in relapsing MS require further investigation.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of systemic natural alpha-interferon in patients with relapsing multiple sclerosis.
• To assess changes in exacerbation rates and neurologic function after completing interferon treatment.

Main Methods:

• A cohort of twelve relapsing MS patients previously treated with subcutaneous natural alpha-interferon was reexamined.
• Data collected included clinical interviews and neurologic assessments.
• Follow-up occurred 4.3 years after initiating treatment and 2.3 years after study completion.

Main Results:

• A significant reduction in the annual exacerbation rate was observed, decreasing from 1.33 to 0.47.
• Overall neurologic function and disability showed no significant changes.
• Six patients demonstrated stabilization or improvement in their condition, maintaining normal daily activities.
• No long-term adverse side effects were reported.

Conclusions:

• Systemic natural alpha-interferon demonstrated a prolonged beneficial effect in relapsing MS patients, primarily through immunomodulation rather than antiviral activity.
• The systemic route may offer comparable efficacy to intrathecal administration with potentially reduced risks.
• Further research into the immunoregulatory mechanisms of systemic interferon in MS is warranted.